期刊
LEUKEMIA
卷 20, 期 1, 页码 35-41出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.leu.2404006
关键词
acute promyelocytic leukemia; extramedullary relapse; all-trans retinoic acid
We analyzed the incidence, presenting features, risk factors of extramedullary ( EM) relapse occurring in acute promyelocytic leukemia (APL) treated with all-trans retinoic acid ( ATRA) and chemotherapy by using a competing-risk method. In total, 740/806 (92%) patients included in three multicenter trials (APL91, APL93 trials and PETHEMA 96) achieved CR, of whom 169 (23%) relapsed, including 10 EM relapses. Nine relapses involved the central nervous system (CNS) and one the skin, of which two were isolated EM relapse. In patients with EM disease, median WBC count was 26 950/mm(3) (7700-162000). The 3-year cumulative incidence of EM disease at first relapse was 5.0%. Univariate analysis identified age < 45 years (P = 0.05), bcr3 PML-RAR alpha isoform (P = 0.0003) and high WBC counts (>= 10000/ mm 3) (P < 0.0001) as risk factors for EM relapse. In multivariate analysis, only high WBC count remained significant (P = 0.001). Patients with EM relapse had a poorer outcome since median survival from EM relapse was 6.7 months as compared to 26.3 months for isolated BM relapse (P = 0.04). In conclusion, EM relapse in APL occurs more frequently in patients with increased WBC counts (X10000/mm(3)) and carries a poor prognosis. Whether CNS prophylaxis should be systematically performed in patients with WBC X10000/mm(3) at diagnosis remains to be established.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据